title: Thrombostatin inhibits induced canine coronary thrombosis.
abstract: Thrombostatin (RPPGF), an angiotensin converting enzyme metabolite of bradykinin, is an inhibitor of alpha-thrombin's ability to activate platelets. We examined the in vivo pharmacokinetics and pharmacodynamics of thrombostatin in rabbits and its ability to inhibit coronary thrombosis induced by electrolytic injury in dogs. Plasma half-life of thrombostatin had a t1/2alpha of 2.6 min and a t1/2beta of 24 min in rabbits. Ligating the renal arteries did not prolong clearance (t1/2alpha = 2.4 min; t1/2beta = 12 min). Thrombostatin produced a prolonged in vivo antiplatelet effect. At 30 min after a single intravenous administration in rabbits, thrombostatin's plasma concentration was <8.7 microM (5 microg/ml). However, ex vivo 20 and 40 nM gamma-thrombin-induced platelet aggregation of these rabbits' platelets was inhibited 40% for 2.75 and 1 h, respectively. In vitro, flow cytometry studies revealed that thrombostatin specifically bound to human platelets and washed human platelets treated with thrombostatin were less responsive to gamma-thrombin than control platelets. Using electrolytic injury to induce coronary artery thrombosis, dogs treated with thrombostatin, aspirin, or combined thrombostatin and aspirin occluded in 62+/-25 (mean +/- SD), 62+/-36, or 89+/-32 min versus untreated animals which occluded at 39+/-27 min, (p<0.01, p<0.01 and p<0.001, respectively). These studies show that thrombostatin binds to platelets and can delay coronary occlusion in vivo.
authors.affiliation: Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor 48109-0640, USA.
authors.forename: A A
authors.initials: AA
authors.lastname: Hasan
authors.forename: S S
authors.initials: SS
authors.lastname: Rebello
authors.forename: E
authors.initials: E
authors.lastname: Smith
authors.forename: S
authors.initials: S
authors.lastname: Srikanth
authors.forename: S
authors.initials: S
authors.lastname: Werns
authors.forename: E
authors.initials: E
authors.lastname: Driscoll
authors.forename: J
authors.initials: J
authors.lastname: Faul
authors.forename: D
authors.initials: D
authors.lastname: Brenner
authors.forename: D
authors.initials: D
authors.lastname: Normolle
authors.forename: B R
authors.initials: BR
authors.lastname: Lucchesi
authors.forename: A H
authors.initials: AH
authors.lastname: Schmaier
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D001241:Aspirin / Q000008:administration & dosage / Q000494:pharmacology; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism; D001920:Bradykinin / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D003328:Coronary Thrombosis / Q000209:etiology / Q000517:prevention & control*; D004285:Dogs; D006801:Humans; D066298:In Vitro Techniques; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D010455:Peptides / Q000737:chemistry; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology; D011817:Rabbits; D013917:Thrombin / Q000494:pharmacology
chemical_list: D010446:Peptide Fragments; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; C079000:bradykinin (1-5); D013917:Thrombin; D001241:Aspirin; D001920:Bradykinin